Radiopharm Theranostics Limited (RADX)
Nasdaq · Healthcare · Biotechnology
$1.27−10.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $18.5M
- 52-week range
- $1.00 – $16.25
- 52-week change
- −79.83%
- EPS (trailing)
- −$3.64
- Analyst rating
- 1.2 Strong buy
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Headquarters: Carlton, Australia · 14 employees · radiopharmtheranostics.com